

URGENT "DRUG RECALL"

Eli Lilly Canada Inc.
Glucagon
Lot D239382A

September 25, 2021

Dear Patient:

Eli Lilly Canada Inc. is voluntarily recalling to the retail level one specific lot of Glucagon in cooperation with Health Canada. The recall extends to lot **D239382A**.

The following table lists the product label and information for the lot impacted by this recall.

Affected Product:

Product Name	Product Code	DIN	UPC	Dosage and Form	Lot Number	Expiration Date
Glucagon	MS8085001CA	02243297	773007808503	1 mg/vial Powder for Solution	D239382A	2022-MA-10

Eli Lilly Canada Inc. is voluntarily recalling lot D239382A, Expiration May 2022, of Glucagon for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the retail level. Lilly is recalling lot D239382A to the patient level because of a product complaint reporting that the vial of Glucagon was in liquid form instead of the powder form. The firm's investigation indicates that the liquid in this Glucagon vial could be related to the manufacturing process. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.

Severe hypoglycemia in patients with diabetes, if not reversed, can potentially cause adverse health consequences ranging from transient, minor complaints to neurological damage, seizures, and even death if not promptly treated. Associated with the one product complaint, it was reported to Lilly that the involved patient experienced lack of drug effect and also reported subsequent seizures.

Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority. We take our obligations seriously and have rigorous quality systems in place to ensure compliance with stringent regulatory requirements.

Adverse reactions or quality problems experienced with the use of this product may be reported to Lilly Canada Inc. at (phone) 1-88-545-5972 or (fax) 1-88-898-2961 or Health Canada to the Canada Vigilance Program by reporting online at www.healthcanada.gc.ca/medeffect, calling toll-free at 1-866-234-2345, or by completing a Canada Vigilance Reporting Form and faxing toll-free to 1-866-678-6789 or mailing to Canada Vigilance Program, Health Canada, Postal Locator 0701D, Ottawa, Ontario, K1A 0K9.

Consumers in possession of Glucagon lot D239382A should contact their pharmacy no later than **October 29th** for return and replacement instructions for the product and should contact their health care provider for guidance. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

Please be certain to carefully review your lot number and return only the affected lot of **Glucagon** listed in the table of Affected Product.

Your immediate attention to the above instructions is greatly appreciated.

We regret any inconvenience caused by this recall. If you require any assistance, please contact the Eli Lilly Canada Customer Response Centre at (phone) 1-888-545-5972 or (fax) 1-888-898-2961.

Eli Lilly Canada Inc. thanks you for your cooperation and assistance.

Sincerely,

Sandra Usik
Associate Vice President, Regulatory Affairs, Quality and Safety
Eli Lilly Canada Inc.